Nathalie Hennuyer

Lille, 59000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Discovery of pyrimidine-based small activators of insulin degrading enzyme.

Discovery of pyrimidine-based small activators of insulin degrading enzyme.

Journal: European journal of medicinal chemistry

Published: June 10, 2025

Anti-inflammatory, but not lipid-lowering, activity of hepatocyte PPARα improves atherosclerosis in Ldlr-deficient mice.

Anti-inflammatory, but not lipid-lowering, activity of hepatocyte PPARα improves atherosclerosis in Ldlr-deficient mice.

Journal: Science translational medicine

Published: May 28, 2025

Expression of concern: Electrothermal patches driving the transdermal delivery of insulin.

Expression of concern: Electrothermal patches driving the transdermal delivery of insulin.

Journal: Nanoscale horizons

Published: February 20, 2025

Expression of concern: Innovative transdermal delivery of insulin using gelatin methacrylate-based microneedle patches in mice and mini-pigs.

Expression of concern: Innovative transdermal delivery of insulin using gelatin methacrylate-based microneedle patches in mice and mini-pigs.

Journal: Nanoscale horizons

Published: February 19, 2025

LIBX-A401: A Novel Selective Inhibitor of Acyl-CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode.

LIBX-A401: A Novel Selective Inhibitor of Acyl-CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode.

Journal: Angewandte Chemie (International ed. in English)

Published: January 07, 2025

N-Tosyl Hydrazone Benzopyran, a New Ligand of PPARα Obtained from Mapping the Conformational Space of Its Active Site.

N-Tosyl Hydrazone Benzopyran, a New Ligand of PPARα Obtained from Mapping the Conformational Space of Its Active Site.

Journal: Journal of chemical information and modeling

Published: December 25, 2024

Development of 2- and 3-prenylated quinolines and tetrahydroquinolines with PPAR activity: From hit to lead and a novel pan-PPAR agonist as a potential candidate for metabolic syndrome.

Development of 2- and 3-prenylated quinolines and tetrahydroquinolines with PPAR activity: From hit to lead and a novel pan-PPAR agonist as a potential candidate for metabolic syndrome.

Journal: Bioorganic chemistry

Published: December 23, 2024

Expression of concern: Near-infrared light activatable hydrogels for metformin delivery.

Expression of concern: Near-infrared light activatable hydrogels for metformin delivery.

Journal: Nanoscale

Published: December 11, 2024

Synthesis of a new 2-prenylated quinoline as potential drug for metabolic syndrome with pan-PPAR activity and anti-inflammatory effects.

Synthesis of a new 2-prenylated quinoline as potential drug for metabolic syndrome with pan-PPAR activity and anti-inflammatory effects.

Journal: Bioorganic & medicinal chemistry letters

Published: December 12, 2023

Insulin-degrading enzyme inhibition increases the unfolded protein response and favours lipid accumulation in the liver.

Insulin-degrading enzyme inhibition increases the unfolded protein response and favours lipid accumulation in the liver.

Journal: British journal of pharmacology

Published: September 05, 2023

Discovery, Structure-Activity Relationships, and In Vivo Activity of Dihydropyridone Agonists of the Bile Acid Receptor TGR5.

Discovery, Structure-Activity Relationships, and In Vivo Activity of Dihydropyridone Agonists of the Bile Acid Receptor TGR5.

Journal: Journal of medicinal chemistry

Published: August 28, 2023

The ubiquitin-like modifier FAT10 is induced in MASLD and impairs the lipid-regulatory activity of PPARα.

The ubiquitin-like modifier FAT10 is induced in MASLD and impairs the lipid-regulatory activity of PPARα.

Journal: Metabolism: clinical and experimental

Published: August 02, 2023

Showing 1-12 of 45

Last Updated: 09/26/2026